Investors weighing healthcare exposure often encounter a natural pairing: Abbott Laboratories (ABT) and Thermo Fisher Scientific (TMO). Both are large-cap industry leaders with global reach, yet they occupy distinct positions across the healthcare value chain. ABT concentrates on patient-facing medical devices, diagnostics, nutrition, and established pharmaceuticals, while TMO supplies the tools, instruments, and services that power scientific research and drug development. This stock comparison examines recent relative performance, market positioning, and growth drivers to help traders and long-term investors assess which name currently presents a more compelling setup. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
Abbott Laboratories operates across four segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. In recent weeks, the company reported quarterly revenue of roughly $13.0 billion, up about 14.5% year over year, with comparable sales rising approximately 7%. Growth was broad-based, led by cardiovascular devices, electrophysiology, and cancer diagnostics, which benefited from Abbott's acquisition of Exact Sciences earlier in the year.
Sentiment, however, has been tempered by two factors. First, Abbott announced plans to separate its Nutrition business into an independent, publicly traded company, a transaction expected to complete by late 2027. Second, management narrowed its full-year adjusted earnings guidance while lowering its comparable sales growth outlook to roughly 6%, citing near-term headwinds in electrophysiology and moderating diabetes-care growth. These developments contributed to a more cautious tone, even as the stock has outperformed the broader medical-device sector over a six-month horizon.
Thermo Fisher Scientific serves pharmaceutical, biotech, academic, government, and diagnostic customers through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. In recent market activity, the company reported quarterly revenue of about $12.1 billion, up 9%, with organic growth of 6% and adjusted earnings per share (EPS) rising 15%.
Management attributed the acceleration to a strengthening recovery in pharma and biotech end markets, where customer confidence and funding conditions have improved. The company also raised its full-year revenue and adjusted EPS guidance, citing productivity gains, margin expansion, and contributions from recent acquisitions. TMO shares have climbed near their 52-week high, although valuation has expanded alongside the rally, leaving some investors weighing execution risk against continued momentum. From what I see, TMO's momentum looks steadier right now.
The core contrast between these two stocks is where they sit in the healthcare ecosystem. ABT is a diversified operator with substantial consumer-facing exposure through its nutrition franchise and direct medical-device and diagnostic businesses. TMO, by contrast, is a "picks-and-shovels" supplier whose growth is tied to research spending, clinical trials, and biopharma manufacturing volumes.
On recent momentum, TMO has shown stronger, more consistent forward signals: it beat estimates, raised guidance, and trades near highs. ABT posted solid top-line growth but revised its outlook lower and faces execution questions around its planned nutrition separation. Risk profiles also differ—ABT carries regulatory and competitive pressure in medical devices, while TMO is sensitive to customer funding cycles and carries a higher debt load. Valuation further separates them: TMO trades at a premium multiple that embeds higher expectations, whereas ABT offers a more modest valuation and a dividend yield. I’m watching this closely as the trends evolve.
Based on observable trend consistency, earnings momentum, and relative positioning, Tickeron's AI would currently favor TMO. The company's accelerating organic growth, raised guidance, and proximity to a 52-week high reflect a steadier upward trend than ABT, which is navigating a revised outlook and structural change from its nutrition spin-off. While ABT retains attractive diversification and income characteristics, the current balance of catalysts and trend signals leans toward TMO in this comparison.
In my own research process, I often turn to Tickeron’s AI tools to cross-check signals across multiple names. One thing that stands out is how these platforms can highlight pattern consistency and momentum shifts that might not be obvious at first glance. For investors seeking a systematic lens on names like ABT and TMO, they offer a useful, data-driven starting point without replacing your own judgment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The 10-day moving average for ABT crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on ABT as a result. In 43 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 52%.
ABT moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABT advanced for three days, in 170 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 136 of 263 cases where ABT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.
The 10-day RSI Indicator for ABT moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 17 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Moving Average Convergence Divergence Histogram (MACD) for ABT turned negative on November 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 25 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 46%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.722) is normal, around the industry mean (4.142). P/E Ratio (35.461) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.253). Dividend Yield (0.023) settles around the average of (0.011) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of health care products
Industry MedicalNursingServices